Delivery Order SPE2DB24D2003-SPE2DB24FXDB8
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,435.30, is for the delivery of Trulicity 4.5 mg/0.5 ml pens, which are used for the treatment of diabetes. The award is a delivery order under Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,163.84, is for the delivery of Trulicity 4.5 mg/0.5 ml pens, a medication used to manage diabetes. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through...
- This federal contract award, valued at $19,527.77, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Trulicity 1.5 mg/0.5 ml pens, a prescription medication used to manage diabetes. The award is a delivery order under an Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at up to $999,999,999.00 and...
- This federal contract award, valued at $1,444.44, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is a delivery order for the supply of Trulicity 0.75 mg/0.5 ml pens, a medication used to manage diabetes. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves...
- This federal contract award, valued at $1,596.54, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Trulicity 1.5 mg/0.5 ml pens, a medication used to manage diabetes. The contract is a Delivery Order issued under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running...
- This federal contract award, valued at $2,390.74, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is for the delivery of Trulicity 1.5 mg/0.5 ml pens, a medication used to manage diabetes. This is a firm-fixed-price delivery order contract with no set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,081.92, is for the delivery of Trulicity 4.5 mg/0.5 ml pen 0.5ml, a medication used to manage diabetes. This order falls under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026....
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $20,755.28 firm fixed-price delivery order covers the supply of Trulicity 1.5 mg/0.5 ml pens, a medication used to treat type 2 diabetes. This award is part of Amerisourcebergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $26,778.35 firm fixed-price delivery order is for the supply of Trulicity 4.5 mg/0.5 ml pens, a medication used to manage diabetes. The award is not set-aside and is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical...
- This federal contract award, valued at $8,493.20, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Trulicity 1.5 mg/0.5 ml pens, a medication used to manage diabetes. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB24FXDB8Delivery Order
This federal contract award, valued at $26,739.81, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Trulicity 4.5 mg/0.5 ml pens, a medication used to manage diabetes. The award is a delivery order under a broader Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has no set-aside designation, indicating open competition. Amerisourcebergen is a subsidiary of the parent company Cencora, Inc., which also does business as Amerisourcebergen. Cencora, Inc. holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.7k | 3/6/24 |